linjc16/ctgov huggingface dataset:
Vector Analysis of Body Composition in Hospitalized Cirrhotic Patients

Study Overview
=================
Brief Summary
-----------------
Patients with acute decompensation of cirrhosis, or acute on chronic liver failure often present with malnutrition, and due to the in-hospital stay, their nutritional intake can vary widely, with several periods of fasting, and sometimes insufficient nutritional support. Therefore patients are prone to develop malnutrition or, the already present malnutrition worsens its status. Our aim is to evaluate the daily changes in nutritional status in patients with acute decompensation of cirrhosis and evaluate the changes in plasma and serum biomarkers.

Official Title
-----------------
Influence of Acute Decompensation on Body Composition Determined by Bioelectrical Impedance Vector Analysis

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Other: Nutritional assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-75 years old Patients with confirmed cirrhosis. Any etiology Hospitalized with acute decompensation of cirrhosis Signed informed consent Exclusion Criteria: Pregnancy Amputation Incomplete data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in nutritional status | Nutritional status will be measured with bioelectrical impedance analysis (Vector and phase angle) | Daily measurement up to 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of inflammatory cytokines | ELISA's test | Samples will be collected at the baseline evaluation. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver Cirrhosis,Infection, Impedance, Body Composition
PERsonalized Mood Augmentation Trial for Depressed Mood

Study Overview
=================
Brief Summary
-----------------
The goal of this open-label single-arm study is to test personalized behavioral intervention for depressed mood.

Detailed Description
-----------------
The goal of this open-label single-arm study is to test personalized behavioral intervention for depressed mood. After an initial period (2-4 weeks) of mood and lifestyle monitoring using smartphone and smartwatch data, participants will be assigned to an evidenced-based behavioral plan that target their lifestyle for 6 weeks. The trial will evaluate changes in depressed mood, associated health behaviors and cognition.

Official Title
-----------------
PERsonalized Mood Augmentation Trial for Depressed Mood

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Behavioral: Personalized Behavioral Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mild to moderate depression per PHQ9 symptom ratings Exclusion Criteria: active substance abuse/dependence psychotic disorders bipolar disorder eating disorder displaying acutely suicidal behaviors

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Personalized Behavioral Intervention<br>Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns. | Behavioral: Personalized Behavioral Intervention<br>* Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PHQ9 | Depression Symptoms on the Patient Health Questionnaire 9-item (PHQ9) scale, min 0 max 27 with lower scores representing better outcome | 12 weeks |
Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
This study aims to analyze the expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with high grade serous ovarian cancer (HGSOC) and benign gynecologic diseases. The candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC.

Official Title
-----------------
Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer

Conditions
-----------------
High Grade Serous Carcinoma, Ovarian Cancer, Exosomes, Prognosis, Early Diagnosis

Intervention / Treatment
-----------------
* Genetic: Sequencing of miRNA/lncRNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed primary high grade serous ovarian cancer Willing to accepted debulking surgeries and adjuvant chemotherapy Good performance status Aged 18 years or older Signed an approved informed consents Exclusion Criteria: Not meeting all of the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HGSOC group<br>This group includes patients of high grade serous ovarian cancer (HGSOC). | Genetic: Sequencing of miRNA/lncRNA<br>* Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)<br>|
| Control group<br>This group includes patients of benign gynecologic diseases as control. | Genetic: Sequencing of miRNA/lncRNA<br>* Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differential expression of miRNA/lncRNA | Differential expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) will be compared between HGSOC group and control group, hence candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC. | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | The progression-free survival of HGSOC patients will be compared between differential expressed candidate miRNA/lncRNA after they have completed debulking surgeries and adjuvant chemotherapy. | Five years |
Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) CONDUCTOME

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the correlation between functional MEG analysis of the tumor and its periphery and the tumor stage and treatment response.

Detailed Description
-----------------
A better tumor grade definition would provide an optimized surgical care, prognosis and therapeutical response evaluation.

Official Title
-----------------
Magnetoencephalographic Study of Glial Tumors Electromagnetic Signature

Conditions
-----------------
Cerebral Primitive Tumor With Chirurgical Indication

Intervention / Treatment
-----------------
* Other: MEG and MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more or equal than 18 years old patient affiliated to social security or similarly regime informed consent form signed supra-tentorial primitive cerebral tumor Exclusion Criteria: Pregnant women and lactating mothers Ward of court or under guardianship Adult unable to express their consent Person deprived of freedom by judicial or administrative decision Person hospitalized without their consent Person under legal protection Magnetic Resonance Imaging (MRI) contraindication (implanted material non MRI-compatible, ferro-magnetic foreign body, claustrophobia) Patients needed emergency medical care for other pathology severely altered general health (Performance Status 3 or 4)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CONDUCTOME<br>MEG and MRI | Other: MEG and MRI<br>* CONDUCTOME<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) data in tumor grade prediction |  | 1 week before exeresis | 
| anatomopathologic and clinical data in tumor grade prediction |  | 1 week after exeresis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of molecules involved in glial cells neuralisation expression in tumor samples |  | Up to 1 month after surgery | 
| Tumoral growth modelisation from patient MEG and MRI data |  | Up to 1 month after surgery |
Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus Intestinal Carriage

Study Overview
=================
Brief Summary
-----------------
This study aims to reduce the duration of VRE intestinal carriage by the administration of Lactobacillus casei rhamnosus (strain Lcr 35 LC). Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic (10 9 lactobacillus bid) or to a 5 weeks regimen with placebo.A stool culture will be performed every week for 5 weeks (during the administration of treatment) then every two weeks until 3 consecutive negative stool culture for VRE.

Detailed Description
-----------------
This study aims to reduce the duration of VRE intestinal carriage by the administration of Lactobacillus casei rhamnosus (strain Lcr 35 LC). Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic (10 9 lactobacillus bid) or to a 5 weeks regimen with placebo.A stool culture will be performed every week for 5 weeks (during the administration of treatment) then every two weeks until 3 consecutive negative stool culture for VRE.

Official Title
-----------------
Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus (VRE) Intestinal Carriage : a Double Blind Randomized Pilot Study

Conditions
-----------------
Vancomycin Resistant Enterococcus Intestinal Carriage

Intervention / Treatment
-----------------
* Drug: Lactobacillus casei rhamnosus (strain Lcr 35 LC)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18; Vancomycin Resistant Enterococcus intestinal carriage Exclusion Criteria: Neutropenia <1000 /mm3, Immunosuppressive drugs, Inhalation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of the duration of Vancomycin Resistant Enterococcus intestinal carriage. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vancomycin Resistant Enterococcus, probiotic
Effect of Naringenin and Beta Carotene on Energy Expenditure

Study Overview
=================
Brief Summary
-----------------
This study is designed to test the effects of the combination of naringenin (from an extract of sweet oranges) and beta carotene on energy expenditure and glucose metabolism in a single human subject.

Detailed Description
-----------------
The subject will be treated for 8 weeks with the combination of naringenin + beta carotene. We will conduct the following assessments before the treatment and at the end of eight weeks. Resting metabolic rate Oral glucose tolerance test with glucose and insulin Ambulatory blood pressure Recording of adverse events Body weight

Official Title
-----------------
Case Study to Evaluate the Safety and Effect on Energy Expenditure of Naringenin and Beta Carotene

Conditions
-----------------
Energy Expenditure, Safety Issues, Glucose Metabolism

Intervention / Treatment
-----------------
* Dietary Supplement: naringenin and beta carotene


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fasting blood glucose < 200mg/dL Exclusion Criteria: Known allergy to citrus fruits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: Case study in a single human subject
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Naringenin + Beta carotene<br>Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day | Dietary Supplement: naringenin and beta carotene<br>* Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy expenditure | Ventilated hood | Five hours | 
| Incidence of Treatment-Emergent Adverse Events | Adverse events | Eight weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose metabolism | Oral glucose tolerance test with insulin | Three hours | 
| Blood pressure | Ambulatory | 24 hours | 
| Body weight | Measurement of body weight | 16 weeks |
Screening for GDM in Women With PCOS and Controls

Study Overview
=================
Brief Summary
-----------------
Women with polycystic ovary syndrome (PCOS) are often insulin resistant. During pregnancy, insulin sensitivity decreases. The investigators examine glucose metabolism during oral glucose tolerance test and the incidense of gestational diabetes mellitus in a prospective cohort of pregnant women with PCOS and controls.

Official Title
-----------------
Glucose Metabolism and Screening for Gestational Diabetes Mellitus According to Different Sets of Criteria in Women With Polycystic Ovary Syndrome and Controls

Conditions
-----------------
Polycystic Ovary Syndrome, Gestational Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: OGTT by randomization
* Other: OGTT by indication


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnancy achieved during 2010-2012 Residents of the municipality of Odense Exclusion Criteria: Moving from Odense during pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: OGTT by randomization<br>Women without risk factors for GDM are offered OGTT in gestational week 28 | Other: OGTT by randomization<br> <br> |
| Experimental: OGTT by indication<br>Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28 | Other: OGTT by indication<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gestational diabetes mellitus | Gestational diabetes mellitus diagnosed by oral glucose tolerance test in gestational week 28 in women with and without risk factors for gestational diabetes mellitus. | 2 years | 
| Gestational Diabetes Mellitus | Gestational diabetes mellitus is diagnosed by 2 hour 75 gram oral glucose tolerance test in gestational week 28 | Gestational week 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anthropometric measures in offspring | The association between blood glucose values and anthropometric measures (birth length, weight and abdominal circumference) at birth in the offspring is investigated | At birth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PCOS, GDM, OGTT, Glucose metabolism
Bioavailability of Ubiquinol in Huntington Disease

Study Overview
=================
Brief Summary
-----------------
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals. Most studies of CoQ have looked at only one formulation of CoQ (ubiquinone) in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ (ubiquinone) to a different formulation (ubiquinol) have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Official Title
-----------------
Bioavailability of Ubiquinol in Huntington Disease

Conditions
-----------------
Huntington Disease

Intervention / Treatment
-----------------
* Dietary Supplement: ubiquinol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have manifest Huntington disease Be 18 years of age or older Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit Exclusion Criteria: Have a history of intolerability of sensitivity to CoQ Have an unstable medical or psychiatric illness Be pregnant or breastfeeding; women of childbearing age must use reliable contraception

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ubiquinol<br>up to 600 mg per day, oral capsules for 8 weeks | Dietary Supplement: ubiquinol<br>* up to 600 mg per day, oral capsules for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum coenzyme Q10 levels |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ubiquinol, coenzyme Q10, Huntington disease
Pre-operative Blood Lipid Level and Post-operative Major Adverse Cardiac Event

Study Overview
=================
Brief Summary
-----------------
Whether the pre-operative blood lipid level and post-operative cardiovascular events is associated is unknown. This study is to find out the main blood lipid and relative protein level change and the post-operative cardiovascular events occurrence.

Detailed Description
-----------------
The participants collected data from their hospital.Patients under going non-cardiac surgery were collected. Data of Triglycerides, cholesterol, Low-density lipoprotein and High-density lipoprotein were collected perioperatively. The postoperative major cardiovascular and cerebral events were also identified and collected. Other data including perioperative information and surgeries and anesthesia data were gathered. Logistic regression models were built and selected. Independent risk factors relative to postoperative major cardiovascular and cerebral events were screened and identified. different levels of Triglycerides, cholesterol, Low-density lipoprotein and High-density lipoprotein were analysed.

Official Title
-----------------
The Relationship of Pre-operative Blood Lipid Level and Post-operative Major Adverse Cardiac Event Occurence

Conditions
-----------------
Lipid Metabolism Disorders, Postoperative Complications

Intervention / Treatment
-----------------
* Diagnostic Test: laboratory test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non-cardiac surgery patients with preoperative blood lipid tests Exclusion Criteria: electronic records missing or peri-operative data missing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal blood lipid/protein group<br> | Diagnostic Test: laboratory test<br>* laboratory test<br>|
| abnormal blood lipid/protein group<br> | Diagnostic Test: laboratory test<br>* laboratory test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular events | such as acute myocardial infarction | 30 days postoperatively |